HC Wainwright Reaffirms “Buy” Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

HC Wainwright restated their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $11.00 price target on the stock.

Several other research analysts have also weighed in on CRVS. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Oppenheimer boosted their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. LADENBURG THALM/SH SH increased their price target on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $5.10 on Tuesday. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The company has a market cap of $327.73 million, a P/E ratio of -5.48 and a beta of 1.05. The stock’s 50-day simple moving average is $7.20 and its 200 day simple moving average is $5.52.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avity Investment Management Inc. lifted its stake in shares of Corvus Pharmaceuticals by 7.6% during the 4th quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after buying an additional 2,100 shares during the last quarter. Nwam LLC bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at about $53,000. XTX Topco Ltd bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at about $74,000. Virtu Financial LLC acquired a new stake in Corvus Pharmaceuticals during the third quarter worth approximately $83,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Corvus Pharmaceuticals during the third quarter worth approximately $89,000. 46.64% of the stock is owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.